These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 31229466)

  • 1. Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial.
    Asrani S; Robin AL; Serle JB; Lewis RA; Usner DW; Kopczynski CC; Heah T;
    Am J Ophthalmol; 2019 Nov; 207():248-257. PubMed ID: 31229466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
    Asrani S; Bacharach J; Holland E; McKee H; Sheng H; Lewis RA; Kopczynski CC; Heah T
    Adv Ther; 2020 Apr; 37(4):1620-1631. PubMed ID: 32166538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study.
    Walters TR; Ahmed IIK; Lewis RA; Usner DW; Lopez J; Kopczynski CC; Heah T;
    Ophthalmol Glaucoma; 2019; 2(5):280-289. PubMed ID: 32672669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2).
    Kahook MY; Serle JB; Mah FS; Kim T; Raizman MB; Heah T; Ramirez-Davis N; Kopczynski CC; Usner DW; Novack GD;
    Am J Ophthalmol; 2019 Apr; 200():130-137. PubMed ID: 30653957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One Year of Netarsudil and Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Phase 3, Randomized MERCURY-1 Study.
    Brubaker JW; Teymoorian S; Lewis RA; Usner D; McKee HJ; Ramirez N; Kopczynski CC; Heah T
    Ophthalmol Glaucoma; 2020; 3(5):327-338. PubMed ID: 32768361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension.
    Singh IP; Fechtner RD; Myers JS; Kim T; Usner DW; McKee H; Sheng H; Lewis RA; Heah T; Kopczynski CC
    J Glaucoma; 2020 Oct; 29(10):878-884. PubMed ID: 32826769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study.
    Khouri AS; Serle JB; Bacharach J; Usner DW; Lewis RA; Braswell P; Kopczynski CC; Heah T;
    Am J Ophthalmol; 2019 Aug; 204():97-104. PubMed ID: 30862500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.
    Lewis RA; Levy B; Ramirez N; Kopczynski CC; Usner DW; Novack GD;
    Br J Ophthalmol; 2016 Mar; 100(3):339-44. PubMed ID: 26209587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).
    Serle JB; Katz LJ; McLaurin E; Heah T; Ramirez-Davis N; Usner DW; Novack GD; Kopczynski CC;
    Am J Ophthalmol; 2018 Feb; 186():116-127. PubMed ID: 29199013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.
    Bacharach J; Dubiner HB; Levy B; Kopczynski CC; Novack GD;
    Ophthalmology; 2015 Feb; 122(2):302-7. PubMed ID: 25270273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
    Stalmans I; Lim KS; Oddone F; Fichtl M; Belda JI; Hommer A; Laganovska G; Schweitzer C; Voykov B; Zarnowski T; Holló G
    Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):179-190. PubMed ID: 37615697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension.
    Kopczynski CC; Heah T
    Drugs Today (Barc); 2018 Aug; 54(8):467-478. PubMed ID: 30209441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study.
    Sit AJ; Gupta D; Kazemi A; McKee H; Challa P; Liu KC; Lopez J; Kopczynski C; Heah T
    Am J Ophthalmol; 2021 Jun; 226():262-269. PubMed ID: 33524367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2.
    Wisely CE; Sheng H; Heah T; Kim T
    Adv Ther; 2020 Mar; 37(3):1114-1123. PubMed ID: 31981106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Netarsudil/latanoprost fixed-dose combination for the treatment of open-angle glaucoma or ocular hypertension.
    Radell JE; Serle JB
    Drugs Today (Barc); 2019 Sep; 55(9):563-574. PubMed ID: 31584573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis.
    Lee JW; Ahn HS; Chang J; Kang HY; Chang DJ; Suh JK; Lee H
    Korean J Ophthalmol; 2022 Oct; 36(5):423-434. PubMed ID: 35989070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of topically administered netarsudil-latanoprost fixed dose combination (FDC; Rocklatan™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG).
    Leary KA; Steibel JP; Harman CD; Anderson AL; Komáromy AM
    Vet Ophthalmol; 2021 Nov; 24(6):610-619. PubMed ID: 34085750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension.
    Araie M; Sugiyama K; Aso K; Kanemoto K; Kothapalli K; Kopczynski C; Senchyna M; Hollander DA
    Adv Ther; 2021 Apr; 38(4):1757-1775. PubMed ID: 33629227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Netarsudil and latanoprost ophthalmic solution for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension.
    Aref AA; Geyman LS; Zakieh AR; Alotaibi HM
    Expert Rev Clin Pharmacol; 2019 Dec; 12(12):1073-1079. PubMed ID: 31842637
    [No Abstract]   [Full Text] [Related]  

  • 20. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.